Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP2. Methods of using these compounds for modulation of eIF4E-BP2 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP2 are provided.
Claims What is claimed is: 1. A compound comprising a modified oligonucleotide consisting of 15 to 80 linked nucleosides and having a nucleobase sequence which is at least 80% complementary to nucleotides 803-940 of SEQ ID NO: 4, wherein said compound inhibits the expression of human eIF4E-BP2 mRNA. 2. The compound of claim 1 which is 15 to 50 nucleobases in length. 3. The compound of claim 1 which is 15 to 30 nucleobases in length. 4. The compound of claim 1 wherein the modified oligonucleotide comprises an antisesnse oligonucleotide. 5. The compound of claim 1 wherein the modified oligonucleotide comprises a DNA oligonucleotide. 6. The compound of claim 1 wherein the modified oligonucleotide comprises an RNA oligonucleotide. 7. The compound of claim 1 wherein the modified oligonucleotide comprises an double-stranded oligonucleotide. 8. The compound of claim 1 wherein the modified oligonucleotide comprises a chimeric oligonucleotide. 9. The compound of claim 1 wherein at least a portion of said compound hybridizes with RNA to form an oligonucleotide-RNA duplex. 10. The compound of claim 1 having at least 90% complementarity with nucleotides 803-940 of SEQ ID NO: 4. 11. The compound of claim 1 having at least 95% complementarity with nucleotides 803-940 of SEQ ID NO: 4. 12. The compound of claim 1 having at least 99% complementarity with nucleotides 803-940 of SEQ ID NO: 4. 13. The compound of claim 1 having at least one modified internucleoside linkage, modified sugar, or modified nucleobase. 14. The compound of claim 13 wherein at least one modified sugar comprises a 2'-O-methoxyethyl. 15. The compound of claim 13 wherein at least one internucleoside linkage is a phosphorothioate internucleoside linkage. 16. A compound of claim 1 wherein said nucleobase sequence comprises at least a 13-nucleobase portion of SEQ ID NO: 60 or 61. 17. A compound of claim 1 wherein said nucleobase sequence is selected from the group consisting of SEQ ID NOs 60 or 61. 18. The compound of claim 1 wherein said nucleobase sequence consists of SEQ ID NO: 60 or 61. 19. The compound of claim 1, wherein said nucleobase sequence is complementary to nucleotides 851-870 or nucleotides 868-887, both of SEQ ID No: 4. 20. The compound of claim 1, wherein said nucleobase sequence is complementary to nucleotides 868-887 of SEQ ID NO: 4. 21. The compound of claim 15, wherein the modified nucleobase is a 5-methylcytosine. 22. The compound of claim 1 consisting of a single-stranded oligonucleotide. 23. The compound of claim 1, wherein the modified oligonucleotide comprises: a gap segment consisting of linked deoxynucleosides; a 5' wing segment consisting of linked nucleosides; a 3' wing segment consisting of linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each of said nucleosides of each of said wing segments comprises a modified sugar. 24. The compound of claim 23, wherein the modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynucleosides; a 5' wing segment consisting of five linked nucleosides; a 3' wing segment consisting of five linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each of said nucleosides of each of said wing segments comprises a 2'-O-methoxyethyl sugar; and wherein each internucleoside linkage is a phosphorothioate linkage. 25. The compound of claim 23, wherein the modified oligonucleotide consists of 20 linked nucleosides. 26. A composition comprising a modified oligonucleotide consisting of 15 to 30 linked nucleosides and having a nucleobase sequence comprising at least 12 contiguous nucleobases of a nucleobase sequence selected from among the nucleobase sequences recited in SEQ ID NOs: 60 and 61 or a salt thereof and a pharmaceutically acceptable carrier or diluent. 27. The composition of claim 26, wherein the modified oliginucleotide is a single-stranded oligonucleotide. 28. The composition of claim 26, wherein the modified oligonucleotide consists of 20 linked nucleosides. 29. A composition comprising the compound of claim 26 or a salt thereof and a pharmaceutically acceptable carrier or diluent. 30. The compound of claim 13, wherein the modified sugar is a bicyclic sugar. 